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Abstract
Background: Interleukin 12 (IL-12) is a cytokine that has been reported to exhibit potent tumoricidal effects in
animal tumor models. A combined approach using Paclitaxel and platinum-based doublet chemotherapy is the
most commonly used backbone regimen for treating lung cancer. Despite numerous studies regarding the
anti-tumor effects of IL-12 and the widespread use of conventional chemotherapy, few direct comparisons
of IL-12 and conventional chemotherapy in the treatment of lung cancer have been performed.
Methods: We compared IL-12 to paclitaxel and cisplatin doublet chemotherapy in terms of efficacy against
lung cancer in mouse models. The antitumor effect was measured by survival assays, histological analyses and
imaging analyses. The cytokine levels were assessed using enzyme linked immunosorbent assay (ELISA) and
flow cytometry (FACS). The spleen sizes were measured. CD31, CD105 and Vascular endothelial growth factor
receptor 3 (VEGFR3) were analyzed using immunofluorescence. Matrix metalloprotein-9 (MMP-9) and cadherin
1 (CDH1) transcript levels were measured by quantitative PCR. Tumor cells apoptosis were examined by Tunel
assay.
Results: The results showed that IL-12 treatment inhibited lung tumor growth, resulting in the long-term
survival of lung cancer-bearing mice. Further examination revealed that IL-12 rapidly activated NK cells to
secrete IFN-γ, resulting in the inhibition of tumor angiogenesis. In contrast, paclitaxel and cisplatin doublet
chemotherapy did not show the expected efficacy in orthotopic lung cancer models; the IFN-γ levels were
not increased after this treatment, and the number of peripheral lymphocytes was reduced.
Conclusion: Together, these animal model data indicate that IL-12 shows a better curative effect than PTX +
CDDP doublet chemotherapy.
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Background
Lung cancer is one of the most commonly diagnosed
cancers and the leading cause of cancer deaths globally,
causing more than 1.4 million deaths annually [1, 2].
Paclitaxel (PTX) and cisplatin (CDDP) doublet chemo-
therapy is one of the first-line treatments for patients
with non-small cell lung cancer (NSCLC) and small cell
lung cancer (SCLC) [3–5]. Although this chemothera-
peutic approach can be effective, the survival rates
remain low [3, 6, 7]. Therefore, effective therapeutic ap-
proaches such as immunotherapies are urgently needed.
Interleukin 12 (IL-12) is a pro-inflammatory cytokine
that was originally identified as a natural killer (NK) cell
stimulatory factor (NKSF) and a cytotoxic lymphocyte
maturation factor [8, 9]. Physiologically, IL-12 has been
implicated in the stimulation of NK and T cell prolifera-
tion, the enhancement of NK and CD8+ T cell cytolytic
activity and the induction of cytokine production, par-
ticularly IFN-γ [10, 11]. Furthermore, IL-12 promotes
the differentiation of T helper 1 (TH1) cells, thereby
bridging innate and adaptive immunity [12, 13]. Mice
lacking the IL-12 subunit p35 showed the early appear-
ance and development of a greater number of papilloma
compared with wild-type (WT) mice. Accordingly, the
growth of B16 melanomas is faster in mice that are defi-
cient in the IL-12 receptor chain IL-12Rβ2 compared to
WT mice [14, 15]. Exogenously administered IL-12
exhibits impressive anti-tumor effects in different mur-
ine tumor models such as sarcoma, melanoma, lung car-
cinoma and breast carcinoma [16–18]. Although IL-12
has certain side effects, its curative effect is significant.
The results from IL-12 phase I/II trials in patients with
B-cell lymphoma or Kaposi sarcoma offer great clinical
prospects [19, 20]. Furthermore, recent studies have
shown that IL-12 plus IL-18 can restore intratumoral
NK cell functions in MHC (major histocompatibility
complex) class I-deficient tumors [21, 22].
PTX is a cytoskeletal drug that targets tubulin. By sta-
bilizing microtubules, PTX arrests the cell cycle in the
G0/G1 and G2/M phases and induces cancer cell death
[23]. CDDP is a platinum coordination compound that
has the ability to crosslink the purine bases in DNA,
causing DNA damage and subsequently inducing apop-
tosis in cancer cells [24]. A combined approach using
PTX and platinum-based doublet chemotherapy is the
most commonly used backbone regimen for treating
NSCLC and SCLC [3–5]. The effective induction of
chemotherapy has been shown to be beneficial for the
survival of some lung cancer patients. However, a few
retrospective studies have shown that the benefits of
chemotherapeutic agents were small for patients with
stable disease (SD), and many cases have shown the fail-
ure of conventional chemotherapy in treating advanced
NSCLC [25, 26].
In the present study, we generated two different
orthotopic lung cancer models and showed that IL-12
administration could suppress tumor growth in these
models, leading to long-term survival compared with
the controls. In contrast, PTX + CDDP doublet
chemotherapy did not improve survival compared
with the control in the lung cancer models. To ex-
plore the mechanisms underlying this phenomenon,
we examined IFN-γ, which is an important anti-tumor
effector molecule, and found that the IFN-γ levels
were significantly increased after IL-12 administration.
Further examination revealed that NK cells were
quickly activated and secreted IFN-γ a few hours after
IL-12 administration. In contrast, the IFN-γ levels
were not increased after PTX and CDDP doublet
chemotherapy, and the number of peripheral lympho-
cytes was reduced. Furthermore, the anti-tumor activ-
ity of IL-12 was found greatly reduced in both NK
cell-deficient mice and IFN-γ-deficient mice, suggest-
ing that NK cells and IFN-γ are the primary factors
that mediate the anti-tumor effects of IL-12 in lung
cancer models. Moreover, we observed that IL-12
inhibited tumor angiogenesis via an IFN-γ-dependent
mechanism. These results suggest that IL-12 showed
a greater efficacy than PTX + CDDP doublet chemo-
therapy and may thus provide an effective strategy for
treating lung cancer.
Methods
Mice and cell lines
Female C57BL/6 and BALB/c mice at 7–8 weeks of
age were purchased from the Shanghai Laboratory
Animal Center (Shanghai, China). Female IFN-γ−/−
mice on a C57BL/6 background were a generous gift
from Dr. Shaobo Su (Shantou University Medical Col-
lege, Shantou, China). Female CD4−/− and CD8−/−
mice, all on a C57BL/6 background, were obtained
from Prof. Zhexiong Lian (University of Science and
Technology of China, Hefei, China). Female Nuclear
factor interleukin-3 (Nfil3)−/− mice (without NK cells)
on a C57BL/6 background were a kind gift from Prof.
Tak Wah Mak (University of Toronto, Toronto,
Canada). All mice were maintained under specific
pathogen-free conditions, and all animal experimental
protocols were approved by the Ethics Committee of Ani-
mal Experiments of the University of Science and Technol-
ogy of China (Approval Number: USTCACUC1201051).
LLC cells were obtained from the Chinese Academy of
Sciences Cell Bank (Shanghai, China) and cultured at
37 °C with 5 % CO2 in DMEM supplemented with 10 %
FCS. CT26 cells (a generous gift from Prof. Xuetao Cao,
Zhejiang University School of Medicine, Hangzhou,
China) were cultured at 37 °C with 5 % CO2 in RPMI
1640 supplemented with 10 % FCS.
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Tumor generation and treatment
C57BL/6 mice were injected intrapleurally with 5 × 105
LLC cells in 0.1 ml of PBS to generate an orthotopic
lung cancer model. The tumor-bearing mice were
divided randomly into four groups for imaging and
histological analyses or into five groups for survival ana-
lysis. These groups were administered saline, single
doses of PTX (5 mg/kg of body weight, Cat. No.
H20063662, Beijing HWELLS Co., Ltd.) and CDDP
(5 mg/kg of body weight, Cat. No. H20063662, Nanjing
Pharmaceutical Co., Ltd.), three doses of PTX + CDDP
(5 mg/kg of body weight), and a combined treatment
with recombinant murine IL-12 (rmIL-12; 12 μg/kg of
body weight, Cat. No. 210–12, PeproTech). PTX+ CDDP
were injected intravenously 5 days after tumor inocula-
tion. For the survival analysis, the tumor-bearing mice
were administered three doses of PTX + CDDP once a
week. Eight days after tumor inoculation, three doses of
IL-12 were injected subcutaneously into the forelimb
root of the mice once every other day. Two days later,
this treatment regimen was repeated one time.
To establish a lung metastasis model, BALB/c mice re-
ceived intravenous tail vein injections of 4 × 104 CT26
cells in 0.2 ml of PBS. With the exception of the group
that received three doses of PTX+ CDDP, the groups
and treatments were the same as those described above.
To generate lung cancer models, Nfil3−/−, CD4−/−,
CD8−/− and IFN-γ−/− mice were injected with LLC cells
as described above. PTX and CDDP were not adminis-
tered to these models, and the IL-12 treatment was
administered as described above.
Bioluminescence imaging and analysis
The plasmid vector pcDNA3.1 (Cat. No. V790-20, Invi-
trogen) was engineered and modified to express lucifer-
ase (pcDNA3.0-Luc). LLC and CT26 cells were
transfected with pcDNA3.0-Luc, and the clones with
strong bioluminescence signals (150 μg/ml luciferin, Cat.
No. LUCK-1G, Gold Biotechnology) were expanded and
injected into mice to generate a lung cancer model.
After intravenous tail vein injection of luciferin
(150 μg/g body weight), the mice were anesthetized
with isoflurane and placed into an IVIS imaging chamber
(Caliper Life Sciences, USA). To analyze the biolumines-
cence images, bioluminescent signal emission regions in
whole mice or lung tissue samples were designated, and
the total photon flux per second was quantified and ana-
lyzed using the Living Image software (Xenogen, USA).
Flow cytometric analysis
The spleens of mice were harvested and weighed. Spleen
size was calculated as (width × length × thickness)/2. To
harvest splenocytes, spleens were cut into small pieces
and passed through 200-gauge mesh. Splenocytes were
harvested after RBC lysis and washing. For the intracel-
lular cytokine analysis of IFN-γ, the splenocytes (1 × 106
cell/ml) were incubated for 4 h with PMA (30 ng/ml,
Cat. No. P1585, Sigma-Aldrich), ionomycin (1 μg/ml,
Cat. No. 407952, Merck) and monensin (5 μg/ml; Cat.
No. 46468, Sigma-Aldrich). Subsequently, the spleno-
cytes were washed and blocked to eliminate non-specific
binding using anti-CD16/32 (2.4G2; BD Biosciences).
FITC-anti-NK1.1 and APC-anti-CD3 (BD Biosciences,
USA) were used to stain the extracellular markers. Then,
the cells were fixed, permeabilized, and stained with PE-
anti-IFN-γ. The stained cells were analyzed using a
FACSCalibur flow cytometry system (BD Biosciences),
and the data were analyzed using the FlowJo 7.6 software
(Treestar, USA).
ELISA for cytokine detection
Mouse serum was collected 1 day after treatment. The
levels of IFN-γ were measured using an IFN-γ ELISA kit
(Cat. No. DKW12-2000-096, Dakewe Biotech Company)
according to the manufacturer’s instructions.
Hematoxylin and eosin staining
For the histological analysis, the lung and tumor tissue
sections were fixed in 10 % phosphate-buffered formalin
(pH 7.2) and embedded in paraffin. The tissue sections
(6-μm-thick) were affixed to the sides, deparaffinized,
stained with H&E and examined under a light micro-
scope (Zeiss, Germany).
Immunofluorescence staining
Lung tumor samples were embedded in optimal cutting
temperature compound. Cryosections (9 μm thick) were
air-dried, fixed for 10 min at room temperature using a
1:1 mixture of acetone and methanol and subsequently
blocked to eliminate non-specific binding using 0.5 %
bovine serum albumin (BSA) in PBS for 1 h. The cryo-
sections were incubated with PE-anti-CD31 (BD Biosci-
ences), rabbit anti-VEGFR3 (Cat. No. ab27278, Abcam),
PE-CD105 (BD Biosciences), PE-CD3 and APC-F4/
80(BD Biosciences) for 12 h at 4 °C. After the cryosec-
tions were washed with PBS, they were incubated with
FITC-goat anti-rabbit IgG (Cat. No. sc-2012, Santa Cruz
Biotechnology) for 2 h at 37 °C and subsequently washed
with PBS. The slides were stained with DAPI (Cat. No.
sc-3598, Santa Cruz Biotechnology) for 2 min. Then, the
slides were washed in PBS, and coverslips were mounted
onto the slides using anti-fade reagent (Cat. No. P36930,
Life Technologies). The images were acquired using a
Zeiss LSM 710 confocal microscope (Zeiss, Germany).
The expression regions of CD31, VEGFR3 and CD105
were quantified and analyzed using the Image-Pro Plus
software (Media Cybernetics, USA).
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Quantitative RT-PCR analysis
Total RNA from tumor tissues was isolated using TRIzol
reagent (Catalog No. 51–0700, Invitrogen, Camarillo,
CA, USA). RNA was then reverse transcribed using
Moloney murine leukemia virus reverse transcriptase
(Catalog No. 51–0700, Invitrogen). Quantitative PCR
analysis was performed according to the instructions
using a SYBR Premix Ex Taq (Takara Japan). For ana-
lysis, the expression of target genes was normalized to
the β-actin. All primers were synthesized by Sangon Bio-
tech (China). The primers used to amplify β-actin were
β-actin-F (5′- TTG CCG ACA GGA TGC AGA A-3′)
and β-actin-R (5′- GCC GAT CCA CAC GGA GTA CTT
-3′). The primers used to amplify MMP-9 were MMP-9-F
(5′- GCA GAG GCATAC TTG TAC CG -3′) and MMP-
9-R (5′- TGA TGT TAT GAT GGT CCC ACT TG -3′).
The primers used to amplify CDH1 were CDH1-F (5′-
CAG GTC TCC TCA TGG CTT TGC -3′) and CDH1-R
(5′- CTT CCG AAA AGA AGG CTG TCC -3′). The
primers used to amplify IFN-γ were IFN-γ-F (5′- AAC
GCT ACA CAC TGC ATC T -3′) and IFN-γ-R (5′- GAG
CTC ATT GAATGC TTG G -3′).
Tunel analysis
LLC tumor cells were first co-cultured with PTX +
CDDP (same concentration used in mice) for 12 h.
Then, these cells were examined by micro-imaging and
Tunel. Cryosections of tumor tissues were also examined
by Tunel. Tunel analysis was performed according to
the manufacturer’s instructions using a One Step
TUNEL Apoptosis Assay Kit (Beyotime Biotechnology
China). The images were acquired using a OLYMPUS
IX81 inverted microscope (OLYMPUS, Japan) and a
Zeiss LSM 710 confocal microscope (Zeiss, Germany).
Statistical analysis
The data are shown as the means ± standard error of the
mean (SEM). Significant differences between more than
two groups were determined using ANOVA. Compari-
sons between two groups were performed using two-
tailed unpaired Student’s t-tests (*, P < 0.05; **, P < 0.01).
Survival curves were estimated using the Kaplan-Meier
method, and differences between the groups were deter-
mined using the log-rank test at a minimal P value.
Results
IL-12 shows more efficacy than PTX + CDDP doublet
chemotherapy in orthotopic lung cancer models
To test the efficacy of IL-12 and PTX + CDDP doublet
chemotherapy in the treatment of lung cancer, we gener-
ated two different lung cancer models. As shown in
Fig. 1, after treatment with IL-12 or chemotherapy in
combination with IL-12 (PTX + CDDP + IL-12), mark-
edly fewer lung tumor nodes (the bioluminescent signal
emission region, with the arrows indicating areas of the
hematoxylin and eosin (H&E)-stained sections) were de-
tected in the treatment groups compared with both the
control group and the chemotherapy-treated LLC lung
cancer models. We also conducted a survival assay. As
shown in Fig. 1e, tumor-bearing mice treated with IL-12
or PTX + CDDP + IL-12 showed significant long-term
survival compared with the control and chemotherapy
treatment groups. Remarkably, the mice treated with IL-
12 or PTX + CDDP + IL-12 survived more than 80 days
(Fig. 1e), which suggests the anti-tumor efficacy of IL-12
as monotherapy or in combination with PTX + CDDP.
Although PTX and CDDP have been used as a first-line
chemotherapy treatment for lung cancer, these data
showed that neither a single dose nor three doses of
PTX-CDDP doublet chemotherapy were sufficient to ex-
tend the lives of tumor-bearing mice significantly or to
suppress tumor growth (Fig. 1b-e). Similar results were
shown in the CT26 lung metastasis model (Fig. 2a-d). In
this lung cancer model, the PTX + CDDP + IL-12 treat-
ment showed a better therapeutic effect than the PTX +
CDDP treatment alone and resulted in long-term
survival (Fig. 2c). We also counted the visible tumor
nodes and measured the weight of tumor and lung
tissues as a whole after completion of the treatments.
These data revealed that the IL-12 or PTX + CDDP + IL-
12 treated mice had less visible lung tumor nodes and
lower lung tumor weight compared to the PTX + CDDP
or control groups (Additional file 1: Figure S1). To as-
sess whether PTX + CDDP has an effect on tumor cells,
in vitro and in vivo experiments were performed. The
results showed that PTX + CDDP (same concentration
used in mice) treatment resulted in LLC cell apoptosis
in vitro, however, no apoptosis was detected in LLC
tumor tissues after PTX + CDDP treatment (Additional
file 2: Figure S2). Based on these data, IL-12 showed a
greater efficacy than PTX + CDDP doublet chemother-
apy in the two different lung cancer models.
IL-12 activates the immune system and rapidly stimulates
NK cells to secrete IFN-γ
To investigate the effects of IL-12 and PTX + CDDP
doublet chemotherapy on the immune system, tumor-
bearing mice were treated with IL-12, PTX + CDDP or
NS and then sacrificed. Surprisingly, we observed that
the spleens of tumor-bearing mice treated with IL-12 or
PTX + CDDP + IL-12 were markedly enlarged but that
the spleens of tumor-bearing mice treated with PTX +
CDDP alone were slightly shrunken compared with the
spleens of control mice (Additional file 3: Figure S3).
Subsequently, we isolated mononuclear cells from the
spleens of these mice and quantified the cells. Not-
ably, the number of mononuclear cells from the
spleens of tumor-bearing mice treated with IL-12 or
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PTX + CDDP + IL-12 increased significantly compared
with both the PTX + CDDP-treated mice and the con-
trol mice (Fig. 3e). We examined the IFN-γ transcript
levels in tumor tissues of different groups by quantitative
PCR. The results showed that the IFN-γ transcript levels
in the tumor tissues of the IL-12 or PTX +CDDP + IL-12
groups were much higher than those in the control
group that was treated with PTX + CDDP alone
(Fig. 3b). We also used ELISA to measure the serum
IFN-γ levels in tumor-bearing mice following treat-
ment. As expected, the serum IFN-γ levels in the
tumor-bearing mice that were treated with IL-12 or
PTX + CDDP + IL-12 were much higher than were
those in the control mice. By contrast, almost no
IFN-γ was detected in the sera of tumor-bearing mice
treated with PTX + CDDP (Fig. 3c). To further iden-
tify the immune cell subpopulation responsible for
IFN-γ production, we examined the expression of
intracellular IFN-γ using flow cytometry (Fig. 3a).
Interestingly, IFN-γ secretion by NK cells increased
markedly and rapidly following IL-12 or PTX + CDDP
+ IL-12 treatment. However, the NK cells showed no
IFN-γ secretion after PTX + CDDP treatment com-
pared with the control (Fig. 3d). These data suggest
that IL-12 can activate NK cells rapidly to produce
IFN-γ, whereas PTX + CDDP not only failed to pro-
mote IFN-γ production but also reduced the number
of peripheral lymphocytes to some extent.
NK cells and IFN-γ are essential for the anti-tumor effects
of IL-12
Although earlier results indicate that NK cells in
tumor-bearing mice can be activated to produce IFN-
γ following IL-12 treatment, the role of NK cells in
the IL-12-mediated lung tumor suppression still
needs to be investigated. To further confirm the roles
of NK and IFN-γ in the anti-tumor effects of IL-12,
Nfil3−/− (without NK cells), CD4−/−, CD8−/−, IFN-γ−/−
and WT mice were injected with LLC tumor cells to
establish lung cancer models. Subsequently, the
tumor-bearing mice were treated with IL-12 or NS,
and tumor growth was monitored via whole-body im-
aging (Figs. 4a and 5a). Remarkably, the tumors in
Nfil3−/− mice or in IFN-γ−/− mice grew significantly
faster than did those in the WT, CD4−/− and CD8−/−
mice, as indicated by the bioluminescent signal
emission region. Furthermore, IL-12 treatment inhib-
ited tumor growth in the WT mice but not in the
Nfil3−/− and IFN-γ−/− mice (Fig. 4a and 5a-c). These
results were also confirmed by survival analyses,
which indicated that the tumor-bearing WT mice ex-
hibited significant long-term survival compared with
the tumor-bearing Nfil3−/− and IFN-γ−/− mice after
treatment with IL-12 (Figs. 4b and 5b). We also per-
formed an immunofluorescence assay to evaluate T
cell and macrophage infiltration in tumors. However,
similar macrophage recruitment was observed in all
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Fig. 1 Comparison of the efficacy of IL-12 and PTX + CDDP doublet chemotherapy on LLC tumor-bearing mice. a Treatment regimen in orthotopic
lung cancer models. Tumor-bearing mice were treated with PTX + CDDP+ IL-12, IL-12, PTX + CDDP, saline (as shown). b Imaging of lung tumor tissues.
Fewer lung tumor nodes were detected in IL-12 and PTX + CDDP + IL-12 treatment groups as compared to PTX + CDDP and control
groups. c Pathological examination also showed that fewer lung tumor nodes were detected in IL-12 and PTX + CDDP + IL-12 treatment
groups as compared to PTX + CDDP and control groups. The arrows indicate the areas of the tumor nodes (magnification × 100; scale bar,
200 μm). d The Imaging results were quantified and analyzed. Bioluminescence (photos/s) indicated that, after IL-12 or PTX + CDDP + IL-12
treatment, living tumor cells were markedly decreased compared with PTX + CDDP and control groups (n = 3; means ± SEM, *P < 0.05). e The survival
(Kaplan-Meier) curves of the treated animals are shown; Prolonged survival was observed in IL-12 or PTX + CDDP + IL-12 group as compared to PTX +
CDDP or control group (log-rank test, P < 0.01)
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groups, and all tumor sections exhibited a minimal
infiltration of T cells (Additional file 4: Figure S4).
Collectively, these data indicate that NK cells and
IFN-γ play essential roles in the anti-tumor effects of
IL-12 in these lung cancer models.
IL-12 via mediation of IFN-γ suppresses tumor
angiogenesis
To investigate whether IL-12 via mediated IFN-γ ex-
pression suppresses tumor angiogenesis in lung can-
cer, IFN-γ−/− and WT mice were tumor-burdened
and subsequently treated with IL-12. After the mice
received treatments, lung tumor tissue sections were
processed, and the frozen lung tumor tissue sections
were stained with anti-CD31 and anti-vascular endo-
thelial growth factor receptor 3 (VEGFR3). Confocal
immunofluorescence imaging showed that the lung
tumor tissues from IFN-γ−/− mice had higher levels
of CD31 and VEGFR3 expression than did those
from WT mice (Fig. 6a). Moreover, IL-12 or PTX +
CDDP + IL-12 treatment reduced CD31 and VEGFR3
expression in the lung tumor tissues of WT mice
(Fig. 6a and b). In addition, we observed the co-
localization of CD31 and VEGFR3 in the lung tumor
tissues of WT mice after IL-12 or PTX + CDDP + IL-
12 treatment. However, IL-12 or PTX + CDDP + IL-12
treatment did not reduce CD31 and VEGFR3 expres-
sion in the lung tumor tissues of IFN-γ−/− mice. In
these animals, CD31 and VEGFR3 did not co-localize
and showed dysregulated expression (Fig. 6a). We
also examined another vascular marker CD105 and
found that its expression was reduced in wildtype
but not in IFN-γ−/− tumor-bearing mice after IL-12
treatment (Fig. 6c and d). Reduced blood vessels may
cause an increase in hypoxia that result in more
invasive phenotype [27, 28]. To evaluate invasive
phenotype of different groups, we examined the
transcript levels of matrix metalloprotein-9 (MMP-9)
and cadherin 1 (CDH1) in para-carcinoma tissue.
The results showed that the MMP-9 transcript level
was decreased after IL-12 treatment; however, the
CDH1 transcript level did not change significantly
(Additional file 5: Figure S5). These results may sug-
gest that treatment with IL-12 does not result in a
more invasive phenotype. Taken together, these data
indicate that the IL-12 via mediated inhibition of



























































Fig. 2 Comparison of the efficacy of IL-12 and PTX + CDDP doublet chemotherapy on CT26 tumor-bearing mice. a Whole-body imaging of
tumor-bearing mice on different dates. Expansion of the tumors of IL-12 and PTX + CDDP + IL-12 groups was less than that of PTX + CDDP or
control groups. b Pathological examination also showed that fewer lung tumor nodes were detected in IL-12 and PTX + CDDP + IL-12 treatment
groups as compared to PTX + CDDP and control groups. The arrows indicate the areas of the tumor nodes (magnification × 100; scale bar,
200 μm). c The survival (Kaplan-Meier) curves of the treated animals are shown; A prolonged survival time was observed in PTX + CDDP + IL-12
group as compared to PTX + CDDP or control group (log-rank test, P < 0.01). d The imaging results were quantified and analyzed. The bioluminescence
(photos/s) indicated that after IL-12 or PTX + CDDP + IL-12 treatment tumor growth was markedly slowed compared with PTX + CDDP and control
groups (n = 3; means ± SEM, *P < 0.05)
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Discussion
Lung cancer is the leading cause of cancer deaths world-
wide [1, 2]. Although traditional lung cancer treatments
such as surgery, chemotherapy and radiotherapy remain
widely used, the results of such treatments are not satis-
factory [7]. Thus, different therapeutic approaches
including immunotherapies are being studied.
As a type of immunotherapy, IL-12 has displayed sig-
nificant anti-tumor effects in a variety of animal models
[29–31]. However, conventional chemotherapy remains
one of the most commonly used treatments for lung
cancer. Therefore, comparing the efficacy of IL-12 with
conventional chemotherapies or testing the efficacy of a
combination of IL-12 and chemotherapy against lung
cancer is important. PTX + CDDP doublet chemother-
apy is recommended for treating NSCLC and SCLC
[5, 32]. However, our preliminary results showed that
PTX + CDDP treatment resulted in LLC cell apoptosis
in vitro, and no apoptosis was detected in LLC tumor
tissues after PTX + CDDP treatment (Additional file 2:
Figure S2). Here, we established two different ortho-
topic lung cancer models (Figs. 1 and 2). In contrast
to subcutaneous tumor models, tumor nodes bud
from lung tissues in orthotopic lung cancer models,
thereby mimicking actual lung cancer conditions. To
determine the treatment and dosage regimens of
chemotherapy and IL-12, we referred to previous re-
ports [16, 33–35] and the results of preliminary
experiments.
Interestingly, IL-12 administration via axillary subcuta-
neous injection significantly inhibited lung tumor
growth, resulting in the long-term survival of tumor-
bearing mice (Figs. 1 and 2). However, despite being
administered in either single or multiple doses, PTX +
CDDP doublet chemotherapy did not show the expected
efficacy and improvement in the survival of the lung
cancer models compared with the controls (Figs. 1








































































































































































































Fig. 3 IL-12 activates the immune system and rapidly stimulates NK cells to secrete IFN-γ. a Flow cytometry analysis of IFN-γ-producing lymphocytes
isolated from the spleens of tumor-bearing mice. The expression of IFN-γ in NK cells increased significantly after IL-12 or PTX + CDDP+ IL-12 treatment
as compared to PTX + CDDP treatment or control. b IFN-γ transcript levels in tumor tissues of different groups were measured by quantitative PCR.
The IFN-γ transcript levels in IL-12 or PTX + CDDP + IL-12 groups were much higher than those in the PTX + CDDP or control groups. (n = 3; means ±
SEM, **P < 0.01). c The IFN-γ serum concentration of different treatments in tumor-bearing mice. The serum IFN-γ levels in IL-12 or PTX + CDDP+ IL-12
groups were much higher than those in the PTX + CDDP or control groups. (n = 3; means ± SEM, **P < 0.01). d The percentages of NK1.1+IFN-γ+ and
CD3+IFN-γ+ cells in the spleens of tumor-bearing mice in different groups. The percentages of NK1.1+IFN-γ+ in IL-12 or PTX + CDDP+ IL-12 groups
were much higher than those in the PTX + CDDP or control groups. (n = 6; means ± SEM, **P < 0.01). e The spleen mononuclear cell numbers from
tumor-bearing mice. More spleen mononuclear cells were found in the IL-12 or PTX + CDDP+ IL-12 groups as compared to PTX + CDDP and control
groups. Less spleen mononuclear cells were found in the PTX + CDDP group compared to the control group (n = 6; means ± SEM, *P < 0.05)
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to act via the direct killing of tumor cells [36]. How-
ever, chemotherapy also affects other systems of the
body, such as the immune system [37]. Differing
views exist regarding the role of conventional chemo-
therapy on the immune system [36–38]. Evidence has
suggested that conventional chemotherapy drugs such
as cyclophosphamide may induce tumor cell death
and stimulate the cross-presentation of dendritic cells
(DCs) [36]. Reports have also demonstrated that PTX
or docetaxel inhibited the NK cell-mediated killing of
K562 target cells effectively in vitro [38, 39]. In the
present study, the further optimization of the chemo-
therapy dosage regimen may bring results that are
more reasonable. However, the decreased number of
immune cells and the attenuation of the host immune
system (Fig. 3) caused by PTX + CDDP treatment may
have contributed to the uncontrolled tumor growth.
The anti-tumor mechanism of IL-12 is complex;
previous studies have suggested that both innate and















































Fig. 4 NK cells are essential for the anti-tumor effects of IL-12. a Whole-body imaging of WT, Nfil3−/−, CD4−/− and CD8−/− tumor-bearing mice.
Tumors detected in the Nfil3−/− group grew more robustly compared to the other groups whether IL-12 was administered or not. b The survival
(Kaplan-Meier) curves of the treated animals are shown; No prolonged survival time was observed in the Nfil3−/− + IL-12 group as compared to
the other groups. c The survival (Kaplan-Meier) curves of the treated animals are shown; A prolonged survival time was observed in the WT + IL-12
group as compared to other groups (log-rank test, P < 0.01)
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12 [17, 40, 41]. The anti-tumor effect of IL-12 on sar-
comas or adenomas, which are considered immuno-
genic cancers [42], is mediated by CD4+ or CD8+ T
cells [16]. In other tumor models, such as EL4, the
IL-12-induced inhibition of tumor growth was shown
to depend on NK and NKT cells [41]. It seems that
the anti-tumor immune responses induced by IL-12
can be divided into two categories: adaptive immunity
mediated primarily via IL-12-induced TH1 polarization, in
which T cells are the primary effector cells, and innate im-
munity mediated via IL-12-activated NK or other innate
immune cells. In one tumor model, the category of the
cellular response induced by IL-12 may depend on tumor
immunogenicity. In this report, we further revealed that
NK cells play a major role in the anti-tumor effects of IL-
12 on lung cancer (Fig. 4a, b). The inoculation of LLC
cells induced a greater amount of tumor growth in NK
cell-deficient mice (Nifl3−/−) than in WT mice. Moreover,
in contrast to WT mice, the tumor growth in NK cell-
deficient mice was not suppressed after IL-12 treatment
(Fig. 4).
Given the importance of IFN-γ for the anti-tumor
effects mediated by IL-12 [40], we used IFN-γ−/− mice to
further confirm the importance of this cytokine (Fig. 5).
The major source of IFN-γ had not yet been elucidated,
as both NK and T cells produce IFN-γ after IL-12
administration [18, 43]. Here, we revealed that NK cells
can be activated rapidly and that intracellular IFN-γ was
detected in these cells six hours after IL-12 administra-
tion. Notably, T cells could not be activated as quickly
(Fig. 3b, e). IFN-γ and a cascade of other secondary and
tertiary pro-inflammatory cytokines were reported to
have a direct toxic effect on the tumor cells and cause
tumor cell apoptosis [10]. Our results may suggest that
IFN-γ may delay the onset of vigorous tumor growth.
IFN-γ has also been reported to promote the inhibition
of angiogenesis [44]. Subsequent experiments confirmed
that CD31+ vessels in lung tumor tissue become ex-
panded and disordered, particularly in the IFN-γ−/− mice
(Fig. 6). Vascular endothelial growth factor receptor 3
(VEGFR3), which is downregulated in quiescent adult
vessels, is upregulated during angiogenesis [45, 46].
Moreover, VEGFR3 was abundantly expressed in lung
tumor tissues, particularly in the IFN-γ−/− mice. Import-
antly, the areas showing VEGFR3 expression did not
overlap with CD31+ vessels in lung tumor tissue, sug-
gesting the formation of new vessels. Further studies
































































Fig. 5 The anti-tumor effect of IL-12 is dependent on IFN-γ. a Whole-body imaging of WT and IFN-γ−/− tumor-bearing mice. Tumors detected in
the IFN-γ−/− groups grew more robustly compared with WT group whether IL-12 was administered or not. b The survival (Kaplan-Meier) curves
of the treated animals are shown. A prolonged survival time was observed in the WT + IL-12 group as compared to other groups (log-rank test,
P < 0.01). No prolonged survival time was observed in the IFN-γ−/− + IL-12 group. c The imaging results were quantified and analyzed.
The bioluminescence (photos/s) indicated that the tumors in IFN-γ−/− mice grew more robustly compared to the WT group whether
IL-12 was administered or not. (n = 6; means ± SEM, **P < 0.01)
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reduced after IL-12 treatment and that weakly expressed
VEGFR3 co-localized with CD31. IFN-γ may also induce
the secretion of the chemokines IFN-γ-inducible pro-
tein 10 (IP-10) and monokine induced by IFN-γ
(MIG) [47, 48]. These chemokines may induce alter-
ations in the extracellular matrix remodeling process
and decrease the expression of adhesion molecules from
the endothelial cells [11, 49]. These mechanisms may lead
to the IL-12-mediated anti-angiogenic effect of IFN-γ.
Toxic side effects are an important factor, which deter-
mines a drug’s clinical application. The Phase I and
Phase II trials of IL-12 in patients with renal cancer were
performed by the Genetics Institute. In the Phase I trial,
the toxicity of IL-12 was acceptable. However, in the
Phase II trial, the administration of IL-12 resulted in
severe systemic toxicity that threatened patients’ lives
[50, 51]. Subsequent investigations have found that the
problem is triggered by the dosing regimen. In the Phase
II study, the patients received consecutive high doses of
IL-12 by intravenous injection. However, the Phase I
trial gave patients various amounts of IL-12 to deter-
mine a maximum safe dose, which formed an “initial
injection” of IL-12. Further studies in mice and cyno-
molgus monkeys revealed that an initial single dose of
IL-12 prevented severe toxicity [50, 52]. In addition, the
route of administration may impact the toxicity of IL-12.
In another two Phase I trials, the toxicities of IL-12
from subcutaneous injection appeared to be mild and
consisted mainly of a flu-like syndrome [53, 54]. Sub-
sequent clinical trials using lower doses of IL-12 with
subcutaneous injection have shown no severe systemic
toxicity [20, 55]. Taken together, through the careful
design of dosing regimen and administration method,
the side effects of IL-12 can be minimized and
acceptable.
Conclusions
In summary, these results demonstrate that IL-12,
either alone or in combination with PTX + CDDP,

























































































































































































Fig. 6 IL-12-induced IFN-γ suppresses tumor angiogenesis. a Immunofluorescence of tumor tissues in WT and IFN-γ−/− tumor-bearing mice. CD31
and VEGFR3 expression in the lung tumor tissues of WT mice was reduced after IL-12 or PTX + CDDP + IL-12 treatment (original magnification,
×100; scale bar, 100 μm). b Percentage of specimens showing CD31 or VEGFR3 expression. CD31 and VEGFR3 expression in the lung tumor tissues
of IFN-γ−/− mice was higher than that of WT. CD31 expression in the lung tumor tissues of WT mice was reduced after IL-12 or PTX + CDDP + IL-
12 treatment (n = 3; means ± SEM, **P < 0.01). c Immunofluorescence of tumor tissues in WT and IFN-γ−/− tumor-bearing mice. CD105 expression
in the lung tumor tissues of WT mice was reduced after IL-12 or PTX + CDDP + IL-12 treatment (original magnification, ×100; scale bar, 100 μm).
d Percentage of specimens showing CD105 expression. CD105 expression in the lung tumor tissues of IFN-γ−/− mice was higher than that of WT.
CD105 expression in the lung tumor tissues of WT mice was reduced after IL-12 or PTX + CDDP + IL-12 treatment (n = 3; means ± SEM, **P < 0.01)
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more efficacy than did PTX + CDDP alone in these
lung cancer models. This mechanism is dependent on
the rapid production of IFN-γ in activated NK cells,
resulting in the inhibition of tumor angiogenesis.
Hence, these findings may provide the basis for com-
bination therapies to treat lung cancers, making this
disease more accessible for targeted immune therapy.
Although IL-12 has some side effects, through careful
design of the dosing regimen and administration
method, side effects can be minimized to acceptable
levels, thus demonstrating that IL-12 is still a candi-
date for anticancer drugs.
Additional files
Additional file 1: Figure S1. Analysis of lung tumor nodes and tumor
lung tissues weight in the four treatment groups. (A) The LLC tumor
nodes and lung tissues were photographed. The visible tumor nodes
were counted, and the final lung tumor tissues were photographed after
completion of the treatments. The tumor and lung tissues as a whole
were weighed. The average visible lung tumor nodes and the weight of
LLC tumor and lung tissues from the IL-12 or PTX + CDDP + IL-12 group
were significantly less than those of the PTX or control group (n = 3;
means ± SEM, **P < 0.01). (B) The CT26 tumor nodes and lung tissues
were photographed. The visible tumor nodes were counted, and the
final lung tumor tissues were photographed after completion of the
treatments. The tumor and lung tissues as a whole were weighed. The
average visible lung tumor nodes and the weight of CT26 tumor and
lung tissues from the IL-12 or PTX + CDDP + IL-12 group were significantly
less than those of the PTX or control group (n = 3; means ± SEM, **P < 0.01).
(PDF 61 kb)
Additional file 2: Figure S2. PTX + CDDP induce LLC cell apoptosis in
vitro but not in vivo at the same concentration. (A) LLC cells were
examined by micro-imaging and Tunel assay. PTX + CDDP induced LLC
cell apoptosis in vitro (original magnification, ×200; scale bar, 50 μm). (B)
Cryosections of tumor tissues were examined by Tunel. No apoptosis was
detected in vivo in PTX + CDDP groups (original magnification, ×100;
scale bar, 100 μm). (PDF 129 kb)
Additional file 3: Figure S3. Spleens were enlarged after IL-12 treatment.
(A) The spleen-size was calculated. The spleen-sizes increased significantly
after IL-12 or PTX + CDDP + IL-12 treatment and were slightly reduced after
PTX + CDDP treatment compared to the PTX + CDDP or the control groups
(n = 3; means ± SEM, **P < 0.01). (B) The spleens were weighed. The weights
of spleens increased significantly after IL-12 or PTX + CDDP + IL-12
treatment compared to the PTX + CDDP or control groups (n = 3;
means ± SEM, *P < 0.05). (PDF 36 kb)
Additional file 4: Figure S4. Macrophage and T cell infiltration of
tumors in the four treatment groups. Large number of F4/80+
macrophages infiltrated the tumor tissues in the four groups (original
magnification, ×100; scale bar, 100 μm). Minimal infiltration of CD3+ T
cells in tumor tissues in the four groups (original magnification, ×100;
scale bar, 100 μm). (PDF 159 kb)
Additional file 5: Figure S5. IL-12 treatment did not result in more
invasive phenotype. (A) Matrix metalloprotein-9 (MMP-9) transcript level
in para-carcinoma tissue was measured by quantitative PCR. MMP-9
transcript level was slightly decreased after IL-12 treatment (n = 3;
means ± SEM, *P < 0.05). (B) Cadherin 1 (CDH1) transcript level in
para-carcinoma tissue was measured by quantitative PCR. Similar CDH1
transcript levels were found among the four groups. (PDF 5 kb)
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